BioWorld

Jan. 20, 2005

It's Official: Inex's Marqibo Gets Not-Approvable Letter From FDA

As expected, the FDA turned down Inex Pharmaceuticals Corp.'s Marqibo (vincristine sulfate liposomes injection). (BioWorld Today) Read More

Synta Files For $115M IPO; Proceeds To Push Pipeline

AVI Sky High On Patents, Potential For State Funds

Neoprobe Forms Subsidiary As Home For ACT Platform

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for April 1, 2026.

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026